Orsiro From BIOTRONIK SE & Co.KG, Industry's First Hybrid Drug-Eluting Stent, Performs as Best in Class

BUELACH, SWITZERLAND--(Marketwired - May 30, 2013) -

Highlighted Links

http://www.biotronik.com

Primary end-point results from the BIOFLOW-II Clinical Study demonstrating the non-inferiority of the BIOTRONIK Orsiro Hybrid Drug-Eluting Stent compared to Abbott's XIENCE PRIME^™. These results were presented in a late-breaking clinical trials session at the EuroPCR congress in Paris by principal investigator, Prof. Stephan Windecker, MD of University Hospital Bern, Switzerland.

BIOFLOW-II is a prospective, international, multi-center, randomized trial evaluating the safety and efficacy of Orsiro against XIENCE PRIME^™. The primary endpoint is in-stent late lumen loss at nine months. Secondary clinical endpoints include Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Grafting (CABG) and clinically driven Target Lesion Revascularization (TLR). In addition to angiographic follow-up, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging were performed at nine months. Clinical follow-up took place at one, six and nine months and will continue annually for up to five years.

Between July 2011 and March 2012, 452 patients were enrolled in a 2:1 (Orsiro:XIENCE PRIME^™) randomization at 24 European sites. At nine months, the results for the primary endpoint in-stent late lumen loss were 0.10 +/-0.32 mm in the Orsiro arm and 0.11 +/-0.29 mm in the XIENCE PRIME^™ arm evaluated by an independent core laboratory and confirming the non-inferiority hypothesis (p-value for non-inferiority < 0.0001). No significant differences were reported for the clinical end-points at nine months including: TLF (4.8% for Orsiro vs. 5.3% for XIENCE PRIME^™), Cardiac death (0.7% vs. 0.0%), MI (2.4% vs. 2.6%) and TLR (2.1% vs. 2.7%). Additionally no stent thrombosis was reported in either arm. All clinical events were adjudicated by a Clinical Events Committee (CEC). The OCT subgroup showed significantly better strut coverage for Orsiro (with 98.3% strut coverage for Orsiro vs. 97.5% for XIENCE PRIME^™, p-value =0.042).

"The Orsiro stent met the primary non-inferiority endpoint of late loss at 9 months compared to the XIENCE PRIME^™ stent, demonstrating effectiveness of drug elution from this bioabsorbable polymer," commented Prof. Windecker. "The platform also appears to be safe, with low rates of myocardial infarction and revascularization and no reported stent thrombosis. The low strut thickness and good deliverability of Orsiro is advantageous during complex stenting which is performed in current cath lab practice."

The primary end-point results from the BIOFLOW-III registry were also presented yesterday at the EuroPCR congress in Paris by coordinating investigator Prof. Johannes Waltenberger, MD of Universitätsklinikum Münster, Germany, further demonstrating the clinical benefits of Orsiro.

BIOFLOW-III is an international, prospective, non-randomized, multi-center, open-label clinical evaluation of the Orsiro Hybrid Drug-Eluting Stent. The primary endpoint is Target Lesion Failure (TLF) at 12 months defined as a composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), emergent Coronary Artery Bypass Graft (CABG), and clinically driven Target Lesion Revascularization (TLR). Pre-specified sub-groups include diabetes, small vessels (≤2.75 mm), chronic total occlusion (CTO) and Acute Myocardial Infarction (AMI).

Between August 2011 and March 2012, 1,356 patients were enrolled at 43 sites in 14 countries. At 12 months, the result for the primary endpoint TLF is 4.7%. With a breakdown into cardiac death 1.3%, target vessel MI 2.0%, emergent CABG 0.0% and clinically driven TLR 2.7%.

"The results from this large all comers registry confirms the efficacy and safety of Orsiro in a large and more complex patient population," commented Prof. Waltenberger.

The Orsiro Hybrid Drug-Eluting Stent (DES), launched in 2011, features the latest development in BIOTRONIK stent technology -- a unique hybrid solution that combines passive and active components. PROBIO passive coating encapsulates the stent and minimizes interaction between the metal stent and the surrounding tissue. BIOlute active coating contains a highly biocompatible polymer that delivers a limus drug via a bio-absorbable matrix. This hybrid coating is layered on top of the high performance PRO-Kinetic Energy stent platform, renowned for its advanced thin-strut stent design and outstanding deliverability.

"BIOTRONIK already offers a strong coronary and peripheral passive device portfolio, and we will continue to introduce innovative technologies," commented Alain Aimonetti, Vice President Sales and Business Development, BIOTRONIK Vascular Intervention. "The exciting addition of the Orsiro Hybrid DES allows us to offer the world's most advanced product portfolio for vascular intervention and paves the way for the drug-eluting absorbable scaffold we are developing."

About BIOTRONIK SE & Co. KG
As one of the world's leading manufacturers of cardiovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. Several million heart patients around the world have received BIOTRONIK implants, designed to save and improve the quality of their lives. Since its development of the first German pacemaker in 1963, BIOTRONIK has launched several innovations into the market -- including remote monitoring with BIOTRONIK Home Monitoring® in 2000 and the world's first implantable cardioverter-defibrillators and implantable heart failure therapy devices with ProMRI® technology, approved for MR scanning, in 2012. This year BIOTRONIK is celebrating its 50th anniversary.

For more information, visit: www.biotronik.com